DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease — Stella

Home/Safety Issues/

View on ClinicalTrials.gov

Recruiting

Back to Safety Issues trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

Peking Union Medical College Hospital, Beijing

Key details

Sponsor

Peking Union Medical College Hospital

Enrollment target

~200 participants

Started

September 2022

Primary completion

December 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 85 Years

Last updated December 2022

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.